Division of Hematology, Mayo Clinic, Rochester, MN, USA.
Leuk Lymphoma. 2012 Nov;53(11):2159-65. doi: 10.3109/10428194.2012.690605. Epub 2012 May 21.
The absolute monocyte/lymphocyte count prognostic score (AMC/ALC score) has not been directly compared with the cell of origin (COO) to predict overall survival (OS) and progression-free survival (PFS) in diffuse large B-cell lymphoma (DLBCL). Thus, we retrospectively examined a new cohort of 99 patients with DLBCL treated from 2008 to 2010, (1) to validate whether AMC/ALC score affects survival, (2) to investigate whether AMC/ALC score is independent of COO to predict survival and (3) to assess whether AMC/ALC score can further stratify clinical outcomes by COO. By univariate analysis, the AMC/ALC score was a predictor for OS and PFS. On multivariate analysis performed including the COO and the International Prognostic Index, AMC/ALC score remained an independent predictor for OS and PFS. The AMC/ALC score was able to further stratify DLBCL clinical outcomes by COO. The AMC/ALC score was independent of COO and added to its ability to identify patients with high-risk disease.
绝对单核细胞/淋巴细胞计数预后评分（AMC/ALC 评分）尚未与起源细胞（COO）直接比较，以预测弥漫性大 B 细胞淋巴瘤（DLBCL）的总生存期（OS）和无进展生存期（PFS）。因此，我们回顾性检查了 99 例 2008 年至 2010 年期间治疗的新 DLBCL 患者队列，（1）验证 AMC/ALC 评分是否影响生存，（2）研究 AMC/ALC 评分是否独立于 COO 预测生存，以及（3）评估 AMC/ALC 评分是否可以通过 COO 进一步分层临床结局。通过单因素分析，AMC/ALC 评分是 OS 和 PFS 的预测因子。在包括 COO 和国际预后指数的多因素分析中，AMC/ALC 评分仍然是 OS 和 PFS 的独立预测因子。AMC/ALC 评分能够通过 COO 进一步分层 DLBCL 的临床结局。AMC/ALC 评分独立于 COO，并增加了其识别高危疾病患者的能力。
